CY1108461T1 - Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας - Google Patents
Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζαςInfo
- Publication number
- CY1108461T1 CY1108461T1 CY20081101219T CY081101219T CY1108461T1 CY 1108461 T1 CY1108461 T1 CY 1108461T1 CY 20081101219 T CY20081101219 T CY 20081101219T CY 081101219 T CY081101219 T CY 081101219T CY 1108461 T1 CY1108461 T1 CY 1108461T1
- Authority
- CY
- Cyprus
- Prior art keywords
- body mass
- obg3
- obesity
- reduce body
- brain head
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με τον τομέα της έρευνας της παχυσαρκίας. Η παχυσαρκία είναι ένα πρόβλημα της δημόσιας υγείας το οποίο είναι σοβαρό και διαδεδομένο. Έχει αναγνωριστεί πως μια ένωση, το σφαιρικό OBG3, μειώνει τη λήψη του βάρους στα ζώα. Αυτή η ένωση είναι αποτελεσματική για την μείωση της σωματικής μάζας και για την θεραπεία νόσων και διαταραχών που σχετίζονται με την παχυσαρκία. Αυτές οι νόσοι και οι διαταραχές που σχετίζονται με την παχυσαρκία περιλαμβάνουν την υπερλιπιδαιμία, την αθηροσκλήρωση, τον διαβήτη και την υπέρταση.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17622800P | 2000-01-14 | 2000-01-14 | |
US19808700P | 2000-04-13 | 2000-04-13 | |
US22988100P | 2000-09-01 | 2000-09-01 | |
EP01942383A EP1248849B1 (en) | 2000-01-14 | 2001-01-10 | Obg3 globular head and uses thereof for decreasing body mass |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108461T1 true CY1108461T1 (el) | 2014-04-09 |
Family
ID=27390648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101219T CY1108461T1 (el) | 2000-01-14 | 2008-10-27 | Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1248849B1 (el) |
JP (1) | JP4698914B2 (el) |
AT (1) | ATE405655T1 (el) |
AU (1) | AU785090B2 (el) |
BR (1) | BR0107626A (el) |
CA (1) | CA2383136C (el) |
CY (1) | CY1108461T1 (el) |
DE (1) | DE60135439D1 (el) |
DK (1) | DK1248849T3 (el) |
ES (1) | ES2312450T3 (el) |
IL (2) | IL150554A0 (el) |
MX (1) | MXPA02006834A (el) |
PT (1) | PT1248849E (el) |
WO (1) | WO2001051645A1 (el) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60141827D1 (de) | 2000-05-31 | 2010-05-27 | Serono Genetics Inst Sa | Verwendung des globulären kopfes von acrp30 zur verstärkung der zunahme von muskelmasse und -differenzierung |
WO2003009862A1 (en) * | 2001-07-20 | 2003-02-06 | Genset S.A. | Agonists and antagonists of modumet for use in the treatment of metabolic disorders |
WO2003009864A1 (en) * | 2001-07-23 | 2003-02-06 | Genset S.A. | Agonists and antagonists of disomet for the treatment of metabolic disorders |
WO2003009861A1 (en) * | 2001-07-24 | 2003-02-06 | Genset S.A. | Agonists and antagonists of metabolix in the treatment of metabolic disorders |
WO2003009865A1 (en) * | 2001-07-25 | 2003-02-06 | Genset S.A. | Agonists and antagonists of energen for use in the treatment of metabolic disorders |
WO2003009863A1 (en) * | 2001-07-26 | 2003-02-06 | Genset S.A. | Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders |
WO2003011325A1 (en) * | 2001-07-27 | 2003-02-13 | Genset S.A. | Agonists and antagonists of moceptin for the treatment of metabolic disorders |
WO2003011323A1 (en) * | 2001-07-30 | 2003-02-13 | Genset S.A. | Agonists and antagonists of contabix for use in the treatment of metabolic disorders |
WO2003011321A1 (en) * | 2001-07-31 | 2003-02-13 | Genset S.A. | Agonists and antagonists of cobesin for the treatment of metabolic disorders |
WO2003011324A1 (en) * | 2001-07-31 | 2003-02-13 | Genset S.A. | Agonists and antagonists of moxifin for the treatment of metabolic disorders |
WO2003011318A1 (en) * | 2001-08-01 | 2003-02-13 | Genset S.A. | Agonists and antagonists of famoset for use in the treatment of metabolic disorders |
EP1418935A1 (en) * | 2001-08-01 | 2004-05-19 | Genset S.A. | Genobix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003011320A1 (en) * | 2001-08-02 | 2003-02-13 | Genset S.A. | Agonists and antagonists of obesingen for the treatment of metabolic disorders |
WO2003011322A1 (en) * | 2001-08-02 | 2003-02-13 | Genset S.A. | Agonists and antagonists of genoxin for use in the treatment of metabolic disorders |
WO2003011319A1 (en) * | 2001-08-02 | 2003-02-13 | Genset S.A | Xobesin agonists and antagonists for the treatment of metabolic disorders |
WO2003013581A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Agonists and antagonists of genceptin for the treatment of metabolic disorders |
WO2003013579A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Lypergix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013580A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Tr xidatin agonists and antagonists treatment of metabolic disorders |
WO2003013582A1 (en) * | 2001-08-06 | 2003-02-20 | Genset S.A. | Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
AU2002328173A1 (en) * | 2001-08-07 | 2003-02-24 | Genset S.A. | Omoxin agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013585A1 (en) * | 2001-08-08 | 2003-02-20 | Genset S.A. | Mifaxin agonists and antagonists for use in the treatment of metabolic |
WO2003013584A1 (en) * | 2001-08-09 | 2003-02-20 | Genset S.A. | Xafinix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013604A2 (en) * | 2001-08-09 | 2003-02-20 | Genset S.A. | Migenix agonists and antagonists for use in the treatment of metabolic disorders |
WO2003013583A1 (en) * | 2001-08-10 | 2003-02-20 | Genset S.A. | Faxigen agonists and antagonists in the treatment of metabolic disorders |
WO2003026695A1 (en) * | 2001-09-21 | 2003-04-03 | Genset S.A. | Agonists and antagonists of cylixin for the treatment of metabolic disorders |
DE60224064T2 (de) | 2001-10-05 | 2008-11-20 | Serono Genetics Institute S.A. | Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit |
WO2003041730A1 (en) * | 2001-11-16 | 2003-05-22 | Genset S.A. | Ditacin agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339673A1 (en) * | 2001-11-28 | 2003-06-10 | Genset S.A. | Agonists and antagonists of ryzn for the treatment of metabolic disorders |
US7344843B2 (en) | 2001-11-29 | 2008-03-18 | Serono Genetics Institute S.A. | Agonists and antagonists of prolixin for the treatment of metabolic disorders |
WO2003047615A1 (en) * | 2001-12-05 | 2003-06-12 | Genset S.A. | Dexar agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339683A1 (en) * | 2001-12-05 | 2003-06-17 | Genset S.A. | Agonist and antagonists of redax for the treatment of metabolic disorders |
WO2003049757A1 (en) * | 2001-12-12 | 2003-06-19 | Genset S.A. | Agonists and antagonists of glucomin for the treatment of metabolic disorders |
AU2002339685A1 (en) * | 2001-12-13 | 2003-06-23 | Genset S.A. | Agonists and antagonists of oxifan for the treatment of metabolic disorders |
WO2003049758A1 (en) * | 2001-12-13 | 2003-06-19 | Genset S.A. | Emergen agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339679A1 (en) * | 2001-12-13 | 2003-06-23 | Genset S.A. | Glucomin agonists and antagonists for use in the treatment of metabolic disorders |
AU2002339688A1 (en) * | 2001-12-14 | 2003-06-30 | Genset S.A. | Glucoset agonists and antagonists for use in the treatment of metabolic disorders |
AU2002358467A1 (en) * | 2001-12-21 | 2003-07-15 | Maxygen Aps | Adiponectin fragments and conjugates |
WO2003055509A1 (en) * | 2001-12-26 | 2003-07-10 | Genset S.A. | Agonists and antagonists of bromix for the treatment of metabolic disorders |
US20050288223A1 (en) * | 2002-05-17 | 2005-12-29 | Genset S.A. | OBG3 Fragments Inhibiting The Conversion Of Active OBG3 Into Less Active OBG3 And Other Compositions For Treatment Of Metabolic Disorders |
US7459433B2 (en) | 2002-05-31 | 2008-12-02 | Serono Genetics Institute, S.A. | Homotrimeric extended OBG3 globular head and uses thereof |
EP1641444B1 (en) * | 2003-06-02 | 2016-03-23 | Isis Innovation Limited | Treatment of muscle fatigue |
DK1648952T3 (en) | 2003-06-03 | 2018-05-28 | The Us Gov As Represented By The Department Of Health And Human Services | Dietary supplements and therapeutic compositions comprising (R) -3-hydroxybutyrate derivatives |
CA2542142A1 (en) * | 2003-10-09 | 2005-05-19 | Trustees Of Boston University | Methods and compositions using adiponectin for treatment of cardiac disorders and for stimulation of angiogenesis |
EP2279745B1 (en) * | 2004-03-31 | 2012-02-08 | Kazuhisa Maeda | Adiponectin as endotoxin-neutralising agent |
CN1740195B (zh) * | 2005-04-15 | 2012-01-04 | 复旦大学 | 一种多肽gapM1及其制备方法 |
WO2007147563A1 (en) * | 2006-06-20 | 2007-12-27 | Laboratoires Serono S.A. | Process for globular adiponectin production |
TR201908522T4 (tr) | 2008-01-04 | 2019-07-22 | The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services | Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri. |
EP2088156A1 (en) | 2008-02-08 | 2009-08-12 | Institut Pasteur | Use of adiponectin for the diagnosis and/or treatment of presbycusis |
US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
EP3659595A1 (en) | 2012-11-05 | 2020-06-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869330A (en) * | 1995-06-05 | 1999-02-09 | Whitehead Institute For Biomedical Research | DNA encoding a novel serum protein produced exclusively in adipocytes |
FR2767135B1 (fr) * | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
US6461821B1 (en) * | 1997-10-29 | 2002-10-08 | Otsuka Pharmaceutical Co., Ltd. | Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor |
-
2001
- 2001-01-10 ES ES01942383T patent/ES2312450T3/es not_active Expired - Lifetime
- 2001-01-10 IL IL15055401A patent/IL150554A0/xx unknown
- 2001-01-10 DK DK01942383T patent/DK1248849T3/da active
- 2001-01-10 WO PCT/IB2001/000084 patent/WO2001051645A1/en active IP Right Grant
- 2001-01-10 PT PT01942383T patent/PT1248849E/pt unknown
- 2001-01-10 DE DE60135439T patent/DE60135439D1/de not_active Expired - Lifetime
- 2001-01-10 EP EP01942383A patent/EP1248849B1/en not_active Expired - Lifetime
- 2001-01-10 AT AT01942383T patent/ATE405655T1/de active
- 2001-01-10 BR BR0107626-4A patent/BR0107626A/pt not_active Application Discontinuation
- 2001-01-10 JP JP2001551219A patent/JP4698914B2/ja not_active Expired - Fee Related
- 2001-01-10 MX MXPA02006834A patent/MXPA02006834A/es active IP Right Grant
- 2001-01-10 AU AU57899/01A patent/AU785090B2/en not_active Ceased
- 2001-01-10 CA CA2383136A patent/CA2383136C/en not_active Expired - Fee Related
-
2002
- 2002-07-03 IL IL150554A patent/IL150554A/en not_active IP Right Cessation
-
2008
- 2008-10-27 CY CY20081101219T patent/CY1108461T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1248849B1 (en) | 2008-08-20 |
MXPA02006834A (es) | 2005-07-01 |
CA2383136C (en) | 2012-09-18 |
DK1248849T3 (da) | 2008-12-08 |
BR0107626A (pt) | 2002-10-15 |
AU785090B2 (en) | 2006-09-14 |
EP1248849A1 (en) | 2002-10-16 |
ES2312450T3 (es) | 2009-03-01 |
ATE405655T1 (de) | 2008-09-15 |
AU5789901A (en) | 2001-07-24 |
IL150554A (en) | 2009-05-04 |
DE60135439D1 (de) | 2008-10-02 |
CA2383136A1 (en) | 2001-07-19 |
JP2003519633A (ja) | 2003-06-24 |
IL150554A0 (en) | 2003-02-12 |
JP4698914B2 (ja) | 2011-06-08 |
PT1248849E (pt) | 2008-09-08 |
WO2001051645A1 (en) | 2001-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108461T1 (el) | Σφαιρικη κεφαλη του obg3 και χρησεις αυτου για την μειωση της σωματικης μαζας | |
WO2002002520A3 (en) | Compounds to treat alzheimer's disease | |
EP1390491A4 (en) | METHOD OF TREATING NEURODEGENERATIVE, PSYCHIATRIC AND OTHER DISEASES WITH DEACETYLASE INHIBITORS | |
ATE419863T1 (de) | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit | |
EA200300944A1 (ru) | Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина | |
GB0223038D0 (en) | Therapeutic compounds | |
WO2004054515A3 (en) | Thrombopoietin mimetics | |
ATE272944T1 (de) | Zusammensetzung mit insektabschreckenden eigenschaften | |
MXPA04000442A (es) | Composicion de alimento para mascotas, para regular el peso corporal y evitar la obesidad y trastornos relacionados en mascotas. | |
ATE430732T1 (de) | Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten | |
WO2001070737A3 (en) | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof | |
WO2003010197A3 (en) | Gmg-1 polynucleotides and polypeptides and uses thereof | |
DE60224064D1 (de) | Fragmente des humanen zn-alpha2-glykoproteins und deren verwendung in methoden zur behandlung der fettleibigkeit | |
NO20045138L (no) | Anvendelse av et hestemelkkonsentrat torket pa en hoydispers, biologisk inert matriks | |
RU2001118219A (ru) | Ингибитор ангиогенеза | |
WO2003009871A3 (en) | Inhibitors of plasminogen activator inhibitor for decreasing body mass | |
DE60325275D1 (de) | Verwendung des menschlichen choriongonadotropins in der behandlung von endometriose-symptomen | |
WO2003033534A3 (en) | Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof | |
BR0015996A (pt) | Compostos de triazinona para o tratamento de doenças causadas pela infestação de protozoários parasìticos | |
DE60333917D1 (de) | Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon | |
PT1282414E (pt) | Compostos derivados de felbamato para o tratamento da dor neuropatica | |
EP2177231A3 (en) | Use of goat serum for veterinary treatment | |
WO2003082915A3 (en) | Xcrf polynucleotides and polypeptides and uses thereof | |
BR0007491A (pt) | Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções | |
RU2002125421A (ru) | Способ лечения ожирения |